Key Developments: Derma Sciences Inc (DSCI.OQ)

DSCI.OQ on NASDAQ Stock Exchange Capital Market

8.96USD
11:36am EDT
Price Change (% chg)

$0.23 (+2.63%)
Prev Close
$8.73
Open
$8.82
Day's High
$8.99
Day's Low
$8.82
Volume
3,921
Avg. Vol
29,378
52-wk High
$15.50
52-wk Low
$7.89

Search Stocks

Latest Key Developments (Source: Significant Developments)

Derma Sciences Inc lowers FY 2014 revenue guidance below analysts' estimates
Thursday, 7 Aug 2014 07:30am EDT 

Derma Sciences Inc:Expects FY 2014 net sales to be about $86.0 million.FY 2014 revenue of $91 million - Thomson Reuters I/B/E/S.  Full Article

Derma Sciences Inc affirms FY 2014 revenue guidance
Thursday, 8 May 2014 07:30am EDT 

Derma Sciences Inc:Affirms guidance for 2014 net sales to be about $92.0 million.FY 2014 revenues of $91.8 mln - Thomson Reuters I/B/E/S.  Full Article

Derma Sciences Inc reaffirms FY 2014 revenue guidance
Friday, 14 Mar 2014 07:30am EDT 

Derma Sciences Inc:Affirms FY 2014 guidance for revenues to be about $92 million.FY 2014 revenues of $93 mln - Thomson Reuters I/B/E/S.  Full Article

Derma Sciences Inc closes $86 million underwritten public offering of common stock
Wednesday, 29 Jan 2014 10:17am EST 

Derma Sciences Inc:Closes an underwritten public offering of 7,500,000 shares of common stock.At a price to the public of $11.50 per share, which includes the exercise of the underwriters' option to purchase 978,261 shares of common stock to cover over-allotments.Piper Jaffray & Co. and Canaccord Genuity Inc were joint bookrunning managers for the offering.Oppenheimer & Co Inc and Roth Capital Partners were financial advisors to the company.Total net proceeds to the company were about $80.7 million after deducting the underwriting discount and estimated offering expenses.The company expects to use the proceeds from the offering for the continued development of DSC127, for sales force expansion and for general corporate purposes.  Full Article

Derma Sciences Inc announces pricing of underwritten public offering of common stock
Friday, 24 Jan 2014 09:00am EST 

Derma Sciences Inc:Says it is pricing of an underwritten public offering of 6,521,739 shares of common stock at a price to the public of $11.50 per share.Says it has granted the underwriters a 30-day option to purchase an additional 978,261 shares of common stock to cover over-allotments, if any.Says the offering is expected to close on or about Jan. 29.Says Piper Jaffray & Co. and Canaccord Genuity Inc. are acting as joint bookrunning managers for the offering.Says Oppenheimer & Co. Inc. and Roth Capital Partners are acting as financial advisors to the company.Says gross proceeds from the sale of the shares of common stock are expected to be about $75 mlm, or $86 mln if the underwriters exercise their option to purchase additional shares in full.Says it expects to use the proceeds from the offering for the continued development of DSC127, for sales force expansion, and for general corporate purposes.  Full Article

Derma Sciences Inc announces commencement of public offering of common stock
Thursday, 23 Jan 2014 04:01pm EST 

Derma Sciences Inc:Says that it intends to offer shares of its common stock in a public offering.Says offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.Says Piper Jaffray & Co. and Canaccord Genuity Inc. are acting as joint bookrunning managers for the offering.Says it expects to use the net proceeds from the offering for the continued development of DSC127, for sales force expansion, and for general corporate purposes.  Full Article

Derma Sciences Inc gives FY 2013 revenue guidance below analysts' estimates
Thursday, 16 Jan 2014 07:00am EST 

Derma Sciences Inc:Sees total revenue for FY 2013 to be $79.7 million.FY 2013 revenues of $82.4 million - Thomson Reuters I/B/E/S Estimates.  Full Article

Derma Sciences Inc Acquires 7.3% Of Comvita Ltd's Stake
Wednesday, 4 Sep 2013 08:00am EDT 

Derma Sciences, Inc announced a $7.0 million strategic investment in Comvita Limited, a global natural health and beauty products company based in New Zealand, with the purchase of approximately 2.3 million newly issued common shares. In conjunction with this investment, which represents 7.3% of Comvita's outstanding shares, Edward J. Quilty, Derma Sciences' chairman and chief executive officer, has been named to Comvita's board of directors. The use of proceeds will support Comvita's apiary acquisition and harvest modernization strategy to ensure sufficient supply of medical grade Manuka honey to meet the growing demand for Derma Sciences' MEDIHONEY product line.  Full Article

Faruqi & Faruqi, LLP Launches Investigation Against Derma Sciences Inc For Potential Breaches Of Fiduciary Duties By Board Of Directors
Friday, 19 Apr 2013 08:30pm EDT 

Faruqi & Faruqi, LLP, a national securities firm headquartered in New York City, is investigating the Board of Directors of Derma Sciences, Inc. for potential breaches of fiduciary duties in connection with their conduct in seeking shareholders' approval for an amendment to the Company's 2012 Incentive Plan. Specifically, in the Proxy Statement filed by the Company with the Securities and Exchange Commission on April 12, 2013, the Board of Directors recommends that Derma's shareholders vote to approve an amendment to the Derma Sciences, Inc. 2012 Equity Incentive Plan to increase the number of shares available for issuance thereunder in the amount of 1,687,500 shares. The issuance of the additional shares could have a substantial dilutive effect on the shares of Derma common stock.  Full Article

Derma Sciences Inc Issues FY 2013 Revenue Guidance In Line With Analysts' Estimates-Conference Call
Monday, 1 Apr 2013 11:00am EDT 

Derma Sciences Inc announced that for fiscal 2013 it expects revenue of somewhere in the low $80 millions. According to I/B/E/S Estimates, analysts on an average are expecting the Company to report revenue of $82.84 million for fiscal 2013.  Full Article

Search Stocks